These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8087983)

  • 21. Activation of erythrocyte aldose reductase in man in response to glycaemic challenge.
    Lyons PA; Gould S; Wise PH; Palmer TN
    Diabetes Res Clin Pract; 1991 Oct; 14(1):9-13. PubMed ID: 1748066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes.
    Maeda S; Haneda M; Yasuda H; Tachikawa T; Isshiki K; Koya D; Terada M; Hidaka H; Kashiwagi A; Kikkawa R
    Diabetes; 1999 Feb; 48(2):420-2. PubMed ID: 10334324
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes.
    Hasuike Y; Nakanishi T; Otaki Y; Nanami M; Tanimoto T; Taniguchi N; Takamitsu Y
    Am J Kidney Dis; 2002 Sep; 40(3):464-71. PubMed ID: 12200796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human liver 6-pyruvoyl tetrahydropterin reductase is biochemically and immunologically indistinguishable from aldose reductase.
    Steinerstauch P; Wermuth B; Leimbacher W; Curtius HC
    Biochem Biophys Res Commun; 1989 Nov; 164(3):1130-6. PubMed ID: 2511841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?
    Ito T; Nishimura C; Takahashi Y; Saito T; Omori Y
    Diabetes Res Clin Pract; 1997 Jun; 36(3):161-7. PubMed ID: 9237782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Enzymological Studies on the Mechanisms of Pathogenesis of Diabetic Complications].
    Tanimoto T
    Yakugaku Zasshi; 2018; 138(3):405-415. PubMed ID: 29503433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An aldose reductase from the human erythrocyte.
    Halder AB; Wolff S; Ting HH; Crabbe MJ
    Biochem Soc Trans; 1980 Oct; 8(5):644-5. PubMed ID: 6778746
    [No Abstract]   [Full Text] [Related]  

  • 28. Human erythrocyte aldose and aldehyde reductase.
    Nakayama T; Tanimoto T; Kador PF
    Prog Clin Biol Res; 1989; 290():265-77. PubMed ID: 2498902
    [No Abstract]   [Full Text] [Related]  

  • 29. Epithelial cell density in cataractous lenses of patients with diabetes: association with erythrocyte aldose reductase.
    Kumamoto Y; Takamura Y; Kubo E; Tsuzuki S; Akagi Y
    Exp Eye Res; 2007 Sep; 85(3):393-9. PubMed ID: 17655844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated and unactivated forms of human erythrocyte aldose reductase.
    Srivastava SK; Hair GA; Das B
    Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7222-6. PubMed ID: 3933003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus].
    Shono NI; Rabinovich SE; Platonova LV; Diuzheva TG
    Vopr Med Khim; 1994; 40(5):45-8. PubMed ID: 7839671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidized aldose reductase: in vivo factor not in vitro artifact.
    Grimshaw CE; Lai CJ
    Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
    Oishi N; Kubo E; Takamura Y; Maekawa K; Tanimoto T; Akagi Y
    Br J Ophthalmol; 2002 Dec; 86(12):1363-6. PubMed ID: 12446366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS; Hohman TC; Millen J
    J Med Chem; 1994 Jun; 37(13):2043-58. PubMed ID: 8027986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical localization for aldose reductase in diabetic lenses.
    Akagi Y; Kador PF; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1987 Jan; 28(1):163-7. PubMed ID: 3100473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of human aldehyde reductase: characterization of the active site pocket.
    Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
    Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.
    Smeriglio A; Giofrè SV; Galati EM; Monforte MT; Cicero N; D'Angelo V; Grassi G; Circosta C
    Fitoterapia; 2018 Jun; 127():101-108. PubMed ID: 29427593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldose and aldehyde reductases from human kidney cortex and medulla.
    Robinson B; Hunsaker LA; Stangebye LA; Vander Jagt DL
    Biochim Biophys Acta; 1993 Dec; 1203(2):260-6. PubMed ID: 8268209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.